Table 1. Baseline clinical characteristics of enrolled patients in two groups.
| Variables | All (N=73) | TACE-HAIC group (N=32) | HAIC group (N=41) | P value |
|---|---|---|---|---|
| Age (years) | 59.8±8.8 | 60.4±7.7 | 59.4±9.7 | 0.570 |
| Sex | 0.365 | |||
| Male | 60 (82.2) | 28 (87.5) | 32 (78.0) | |
| Female | 13 (17.8) | 4 (12.5) | 9 (22.0) | |
| HBsAg | 0.242 | |||
| Presence | 42 (57.5) | 21 (65.6) | 21 (51.2) | |
| Absence | 31 (42.5) | 11 (34.4) | 20 (48.8) | |
| Cirrhosis | 0.095 | |||
| Presence | 41 (56.2) | 18 (56.3) | 14 (34.1) | |
| Absence | 32 (43.8) | 14 (43.8) | 27 (65.9) | |
| Ascites | 0.053 | |||
| Presence | 27 (37.0) | 16 (50.0) | 11 (26.8) | |
| Absence | 46 (63.0) | 16 (50.0) | 30 (73.2) | |
| Tumor size (cm) | 9.7±3.2 | 9.2±3.2 | 10.1±3.2 | 0.245 |
| Tumor number | 0.095 | |||
| Single | 32 (43.8) | 18 (56.3) | 14 (34.1) | |
| Multiple | 41 (56.2) | 14 (43.8) | 27 (65.9) | |
| Extrahepatic metastasis | 0.801 | |||
| Presence | 22 (30.1) | 9 (28.1) | 13 (31.7) | |
| Absence | 51 (69.9) | 23 (71.9) | 28 (68.3) | |
| Tumor thrombus | >0.999 | |||
| Presence | 33 (45.2) | 14 (43.8) | 19 (46.3) | |
| Absence | 40 (54.8) | 18 (56.3) | 22 (53.7) | |
| ECOG | 0.787 | |||
| 0 | 56 (76.7) | 24 (75.0) | 32 (78.0) | |
| 1 | 17 (23.3) | 8 (25.0) | 9 (22.0) | |
| CP score | >0.999 | |||
| A | 65 (89.0) | 29 (90.6) | 36 (87.8) | |
| B | 8 (11.0) | 3 (9.4) | 5 (12.2) | |
| WBC (109/L) | 0.102 | |||
| <4.8 | 35 (47.9) | 19 (59.4) | 16 (39.0) | |
| ≥4.8 | 38 (52.1) | 13 (40.6) | 25 (61.0) | |
| HGB (g/L) | 0.223 | |||
| <150 | 49 (67.1) | 24 (75.0) | 25 (61.0) | |
| ≥150 | 24 (32.9) | 8 (25.0) | 16 (39.0) | |
| ALT (U/L) | 0.214 | |||
| <69 | 48 (65.8) | 24 (75.0) | 24 (58.5) | |
| ≥69 | 25 (34.2) | 8 (25.0) | 17 (41.5) | |
| AST (U/L) | 0.234 | |||
| <41 | 41 (56.2) | 15 (46.9) | 26 (63.4) | |
| ≥41 | 32 (43.8) | 17 (53.1) | 15 (36.6) | |
| ALP (U/L) | 0.636 | |||
| <191 | 40 (54.8) | 19 (59.4) | 21 (51.2) | |
| ≥191 | 33 (45.2) | 13 (40.6) | 20 (48.8) | |
| GGT (U/L) | 0.237 | |||
| <249 | 39 (53.4) | 20 (62.5) | 19 (46.3) | |
| ≥249 | 34 (46.6) | 12 (37.5) | 22 (53.7) | |
| ALB (g/L) | 0.059 | |||
| <35 | 35 (47.9) | 11 (34.4) | 24 (58.5) | |
| ≥35 | 38 (52.1) | 21 (65.6) | 17 (41.5) | |
| TBIL (μmol/L) | 0.136 | |||
| <25.5 | 50 (68.5) | 25 (78.1) | 25 (61.0) | |
| ≥25.5 | 23 (31.5) | 7 (21.9) | 16 (39.0) | |
| DBIL (μmol/L) | 0.304 | |||
| <12.5 | 52 (71.2) | 25 (78.1) | 27 (65.9) | |
| ≥12.5 | 21 (28.8) | 7 (21.9) | 14 (34.1) | |
| PT (s) | >0.999 | |||
| <12.8 | 45 (61.6) | 20 (62.5) | 25 (61.0) | |
| ≥12.8 | 28 (38.4) | 12 (37.5) | 16 (39.0) | |
| AFP (ng/mL) | 0.812 | |||
| <400 | 32 (43.8) | 15 (46.9) | 17 (41.5) | |
| ≥400 | 41 (56.2) | 17 (53.1) | 24 (58.5) |
Results in the table are presented as mean ± SD or number (%). TACE, transarterial chemoembolization; HAIC, hepatic arterial infusion chemotherapy; HBsAg, hepatitis B surface antigen; ECOG, Eastern Cooperative Oncology Group; CP, Child-Pugh; WBC, white blood cell; HGB, hemoglobin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, gamma-glutamyl transpeptidase; ALB, albumin; TBIL, total bilirubin; DBIL, direct bilirubin; PT, prothrombin time; AFP, alpha-fetoprotein.